NCT03662854 is a Phase 1 clinical trial of Hair Stimulating Complex (HSC) in Alopecia, sponsored by Histogen.

Who is sponsoring NCT03662854?

NCT03662854 is sponsored by Histogen.

What drugs are being tested in NCT03662854?

Interventions in NCT03662854: Hair Stimulating Complex (HSC), Phosphate Buffered Saline.

Is NCT03662854 still recruiting?

NCT03662854 is currently status unknown. Last updated 21 February 2019.

Last reviewed 2019-02-21 · How we verify

NCT03662854

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

Status unknown Phase 1 Last updated 21 February 2019

What this trial tests

Phase 1 trial testing Hair Stimulating Complex (HSC) in Alopecia in 27 participants. Status unknown.

Timeline

2 July 2018

Primary endpoint
21 January 2019

21 January 2021

Quick facts

Lead sponsor	Histogen
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	27
Start date	2 July 2018
Primary completion	21 January 2019
Estimated completion	21 January 2021
Sites	1 location across United States

Drugs / interventions tested

Hair Stimulating Complex (HSC) — full drug profile →
Phosphate Buffered Saline

Conditions studied

Alopecia — all drugs for Alopecia →

Sponsor

Histogen — full company profile →

Who can join

Adults 40 to 70, female only, with Alopecia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This double-blind placebo-controlled study will assess the tolerability, feasibility, and pharmacodynamics of intradermal Hair Stimulating Complex (HSC) in up to 18 of 27 women with Ludwig 1 or 2 classification or the Savin Frontal classification of hair loss. Safety measures include vital signs, dermatological examination of the scalp, pre- and post-dose blood and urine collection, as well as Investigator Global Assessments and subject self assessments throughout the 22-week study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in Stem Cell-Based Therapy for Hair Loss.
Egger A, Tomic-Canic M, Tosti A. · · 2020 · cited 20× · PMID 32968692

Verify or expand the search:

Other recruiting trials for Alopecia

Currently open trials in the same condition.

NCT07422376 — Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variation · NA · recruiting
NCT07107841 — Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) · NA · recruiting
NCT06998680 — 6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair · NA · recruiting
NCT05484973 — Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss · NA · recruiting
NCT06215469 — Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) · NA · recruiting

Other Histogen trials

Trials by the same sponsor.

NCT05082831 — Human ECM Implanted Within Microfracture Interstices & the Cartilage Defect in the Knee to Regenerate Hyaline Cartilage · Phase 1 · terminated
NCT04803227 — Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19 · Phase 1 · terminated
NCT04435847 — Safety and Efficacy of HST 001 in Male Pattern Hair Loss · Phase 1 · completed
NCT02960204 — Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03662854 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Histogen
Last refreshed: 21 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03662854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing